- Home
- ATAI vs AQST Comparison
ATAI vs AQST Comparison
Compare ATAI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | AQST |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 529.4M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ATAI | AQST |
|---|---|---|
| Price | $7.34 | $4.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $15.88 | $9.00 |
| AVG Volume (30 Days) | ★ 13.7M | 2.7M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,089,000.00 | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1227.60 | 0.77 |
| 52 Week Low | $3.27 | $2.94 |
| 52 Week High | $7.45 | $7.55 |
Technical Indicators
Market Signals| Indicator | ATAI | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 50.32 |
| Support Level | $3.32 | $4.03 |
| Resistance Level | N/A | $5.10 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 50.23 | 18.28 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.